Evidence map›Paper›PMID 35440040›Full record

ArticleActa neuropathologica communications2022

Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.

Elena V Daoud, Kelsey Zhu, Bruce Mickey, Hussein Mohamed, Mandisa Wen, Michael Delorenzo, Ivy Tran, Jonathan Serrano, Kimmo J Hatanpaa, Jack M Raisanen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Elena V Daoud *Department of Pathology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, H2.130, Dallas, TX, 75390-9073, USA.
Kelsey Zhu *Department of Pathology, NYU Langone Medical Center, New York, NY, USA.
Bruce MickeyDepartment of Neurological Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Hussein MohamedDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
Mandisa WenDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
Michael DelorenzoDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
Ivy TranDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
Jonathan SerranoDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
Kimmo J HatanpaaDepartment of Pathology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, H2.130, Dallas, TX, 75390-9073, USA.
Jack M RaisanenDepartment of Pathology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, H2.130, Dallas, TX, 75390-9073, USA.
Matija Snuderl *Department of Pathology, NYU Langone Medical Center, New York, NY, USA.
Chunyu Cai *Department of Pathology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, H2.130, Dallas, TX, 75390-9073, USA. Chunyu.cai@utsouthwestern.edu.ORCID 0000-0001-8808-4779
NYU Langone Health · USSouthwestern Medical CenterSouthwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chordoid meningioma is a morphological variant of meningioma designated as WHO grade 2. However, the recurrence rates varied widely in different case series, and to date, a unifying molecular genetic signature has not been identified. Among 1897 meningiomas resected at our institution, we identified 12 primary chordoid meningiomas from 12 patients. Histologically, all 12 cases had predominant (> 50%) chordoid morphology. Ten were otherwise grade 1, and two were also atypical. We performed DNA global methylation profile, copy number variation analysis, and targeted next-generation sequencing on 11 chordoid meningiomas, and compared to those of 51 non-chordoid, mostly high grade meningiomas. The chordoid meningiomas demonstrated a unique methylation profile in tSNE, UMAP, and hierarchical heatmap clustering analyses of the most differentially methylated CpGs. The most common copy number variation in chordoid meningioma was loss of 1p (7/11, 64%). Three chordoid meningiomas had 2p loss, which was significantly higher than the non-chordoid control cohort (27% vs 7.2%, p = 0.035). 22q loss was only seen in the two cases with additional atypical histological features. Chordoid meningiomas were enriched in mutations in chromatin remodeling genes EP400 (8/11,73%) KMT2C (4/11, 36%) and KMT2D (4/11, 36%), and showed low or absent NF2, TERT, SMO, and AKT1 mutations. Prognosis wise, only one case recurred. This case had atypical histology and high-grade molecular features including truncating NF2 mutation, 1p, 8p, 10, 14, 22q loss, and homozygous deletion of CDKN2A/B. Progression free survival of chordoid, otherwise grade 1 meningioma was comparable to non-chordoid WHO grade 1 meningioma (p = 0.75), and significantly better than chordoid WHO grade 2 meningioma (p = 0.019). Conclusion: the chordoid histology alone may not justify a universal WHO grade 2 designation. Screening for additional atypical histological or molecular genetic features is recommended.

Indexed as

Meningeal NeoplasmsMeningiomaDNA Copy Number VariationsEpigenesis, GeneticHomozygoteHumansSequence DeletionAtypical meningiomaBrain tumorChordoid meningiomaGlobal methylation profilePrognosisWHO grade

Identifiers

PMID35440040
PMCPMC9020042
OpenAlexW4224236003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.